FDA Publishes Article Critical of Vilazodone Data

The Carlat Psychiatry Report, Volume 10, Number 2, February 2012

Glen Spielmans, PhD

Associate professor of psychology, Metropolitan State University, St. Paul, MN

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.

You can't view details of this content, please login or buy subscription here